title: 5-Fluorouracil-based chemotherapy for colorectal cancer and MTHFR/MTRR genotypes.
authors.forename: Barbara
authors.initials: B
authors.lastname: Pardini
authors.forename: Rajiv
authors.initials: R
authors.lastname: Kumar
authors.forename: Alessio
authors.initials: A
authors.lastname: Naccarati
authors.forename: Jan
authors.initials: J
authors.lastname: Novotny
authors.forename: Rashmi B
authors.initials: RB
authors.lastname: Prasad
authors.forename: Asta
authors.initials: A
authors.lastname: Forsti
authors.forename: Kari
authors.initials: K
authors.lastname: Hemminki
authors.forename: Pavel
authors.initials: P
authors.lastname: Vodicka
authors.forename: Justo
authors.initials: J
authors.lastname: Lorenzo Bermejo
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000235:genetics; D018153:Czech Republic; D018572:Disease-Free Survival; D005287:Ferredoxin-NADP Reductase / Q000235:genetics*; D005472:Fluorouracil / Q000627:therapeutic use*; D005838:Genotype; D006801:Humans; D042965:Methylenetetrahydrofolate Reductase (NADPH2) / Q000235:genetics*; D011110:Polymorphism, Genetic
chemical_list: D000964:Antimetabolites, Antineoplastic; C111241:methionine synthase reductase; D005287:Ferredoxin-NADP Reductase; D042965:Methylenetetrahydrofolate Reductase (NADPH2); D005472:Fluorouracil